Compare DKI & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKI | TCRT |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 7.2M |
| IPO Year | 2025 | N/A |
| Metric | DKI | TCRT |
|---|---|---|
| Price | $0.39 | $2.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 157.0K | 34.5K |
| Earning Date | 02-11-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 26.19 | N/A |
| Revenue | ★ $10,204,329.00 | $6,000.00 |
| Revenue This Year | N/A | $5,680,500.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | ★ 100.46 | N/A |
| 52 Week Low | $0.30 | $1.31 |
| 52 Week High | $15.00 | $6.20 |
| Indicator | DKI | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.06 |
| Support Level | N/A | $2.80 |
| Resistance Level | N/A | $3.05 |
| Average True Range (ATR) | 0.00 | 0.27 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 21.53 |
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.